title: Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.
abstract: Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on their clinic effectiveness. These drugs appear to exert their psychedelic effects through their agonist or partial agonist activity at the serotonergic 5-HT2A receptor, though they also have affinity for other metabotropic serotonin receptors. Hallucinogen binding affects a wide range of intracellular signalling pathways, the precise nature of which remains incompletely understood. They alter the serotonergic tone of brainstem raphe nuclei that project through the brain; they interact with receptors in the prefrontal cortex altering connectivity patterns and intracellular functioning; and they disrupt inhibitory control of sensory input via the thalamus to the cortex. The serotonergic system has long been implicated in anxiety and depressive disorders, and is a major target of most existing antidepressants. Classical hallucinogens alter the functioning of this system, but not in the same way current medications do: whilst there are identified receptors and neurotransmitter pathways through which hallucinogens could therein produce therapeutic effects, the neurobiology of this remains speculative at this time. There is currently an extremely limited but growing literature on hallucinogen safety and clinical application. The drugs appear well tolerated by healthy controls and clinical populations, and the rapid tolerance to repeated administration might reduce the possibility of dependency. Clinical trials reported over the past decade have generally shown positive therapeutic potential, but they are notably few in number. Legislative policy has had a freezing effect on evaluation of these compounds, a better understanding of which might improve our knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies.
authors.affiliation: Consultant Psychiatrist, Oxleas NHS Foundation Trust, Princess Royal University Hospital, Orpington, BR6 8NY, UK and Cognition, Schizophrenia and Imaging Laboratory, Department of Psychosis Studies, the Institute of Psychiatry, King's College London, UK.
authors.forename: David
authors.initials: D
authors.lastname: Baumeister
authors.affiliation: Stress, Psychiatry and Immunology Lab, Institute of Psychiatry, Department of Psychological Medicine, Kings College London, London, UK.
authors.forename: Georgina
authors.initials: G
authors.lastname: Barnes
authors.affiliation: Cognition, Schizophrenia and Imaging Laboratory, Department of Psychosis Studies, the Institute of Psychiatry, King's College London, UK.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Giaroli
authors.affiliation: Cognition, Schizophrenia and Imaging Laboratory, Department of Psychosis Studies, the Institute of Psychiatry, King's College London, UK.
authors.forename: Derek
authors.initials: D
authors.lastname: Tracy
keywords: 5-HT2A; LSD; antidepressants; anxiety; depression; hallucinogen; psilocybin
references.citation: Int J Neuropsychopharmacol. 2013 Nov;16(10):2165-80
references.pmid: 23942028
references.citation: J Psychopharmacol. 2011 Nov;25(11):1434-52
references.pmid: 20855349
references.citation: Neuropsychopharmacology. 1997 May;16(5):357-72
references.pmid: 9109107
references.citation: Neurosci Lett. 2011 Apr 15;493(3):76-9
references.pmid: 21276828
references.citation: J Psychopharmacol. 2013 Dec;27(12):1090-106
references.pmid: 23704363
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43
references.pmid: 22308440
references.citation: Front Cell Neurosci. 2013 Jun 19;7:93
references.pmid: 23801939
references.citation: J Psychopharmacol. 2008 Aug;22(6):621-32
references.pmid: 18593735
references.citation: CNS Drugs. 2013 Sep;27(9):703-16
references.pmid: 23757185
references.citation: Am J Psychiatry. 2002 Mar;159(3):419-29
references.pmid: 11870006
references.citation: Neuropsychopharmacology. 1999 Jun;20(6):565-81
references.pmid: 10327426
references.citation: J Nerv Ment Dis. 2014 Jul;202(7):513-20
references.pmid: 24594678
references.citation: Ther Adv Psychopharmacol. 2012 Oct;2(5):179-88
references.pmid: 23983973
references.citation: Brain Sci. 2013 Apr 26;3(2):642-69
references.pmid: 24961419
references.citation: Brain Res. 1999 Apr 17;825(1-2):161-71
references.pmid: 10216183
references.citation: Prog Neurobiol. 2009 May;88(1):17-31
references.pmid: 19428959
references.citation: Neuropharmacology. 1997 Apr-May;36(4-5):589-99
references.pmid: 9225284
references.citation: Neuroscience. 2009 Feb 18;158(4):1406-15
references.pmid: 19111907
references.citation: Trends Pharmacol Sci. 2008 Sep;29(9):454-64
references.pmid: 18676031
references.citation: Nat Rev Neurosci. 2010 Sep;11(9):642-51
references.pmid: 20717121
references.citation: Nature. 2008 Oct 16;455(7215):894-902
references.pmid: 18923511
references.citation: J Pharmacol Exp Ther. 2008 Nov;327(2):316-23
references.pmid: 18708586
references.citation: Arch Gen Psychiatry. 2004 Jan;61(1):34-41
references.pmid: 14706942
references.citation: J Psychopharmacol. 2013 Dec;27(12):1084-9
references.pmid: 24067790
references.citation: Science. 2006 Jul 28;313(5786):536-40
references.pmid: 16873667
references.citation: J Neurosci. 2007 Jun 27;27(26):6956-64
references.pmid: 17596444
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9870-5
references.pmid: 17535909
references.citation: Curr Psychiatr Ther. 1981;20:275-83
references.pmid: 7326971
references.citation: Mol Pharmacol. 2013 Jan;83(1):42-50
references.pmid: 23034456
references.citation: J Neurosci. 2013 Jun 19;33(25):10544-51
references.pmid: 23785166
references.citation: J Nerv Ment Dis. 1996 Feb;184(2):86-94
references.pmid: 8596116
references.citation: Science. 2013 May 3;340(6132):610-4
references.pmid: 23519210
references.citation: Dev Psychobiol. 2012 Sep;54(6):578-89
references.pmid: 21432850
references.citation: J Pharmacol Exp Ther. 1995 Dec;275(3):1638-46
references.pmid: 8531139
references.citation: Nat Rev Neurosci. 2013 Aug;14(8):577-85
references.pmid: 23756634
references.citation: Annu Rev Clin Psychol. 2012;8:49-76
references.pmid: 22224834
references.citation: Psychopharmacology (Berl). 1998 Apr;136(4):409-14
references.pmid: 9600588
references.citation: Neuroreport. 1998 Dec 1;9(17):3897-902
references.pmid: 9875725
references.citation: Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92
references.pmid: 16826400
references.citation: Biol Psychiatry. 2008 Sep 15;64(6):527-32
references.pmid: 18571629
references.citation: PLoS One. 2012;7(8):e42421
references.pmid: 22905130
references.citation: Schizophr Bull. 2013 Nov;39(6):1343-51
references.pmid: 23044373
references.citation: J Pharmacol Exp Ther. 2006 Feb;316(2):892-9
references.pmid: 16254131
references.citation: Neuron. 2007 Feb 1;53(3):439-52
references.pmid: 17270739
references.citation: Am J Psychiatry. 2001 Jun;158(6):899-905
references.pmid: 11384897
references.citation: Lancet. 2010 Nov 6;376(9752):1558-65
references.pmid: 21036393
references.citation: Neuroscience. 1993 Mar;53(2):457-63
references.pmid: 8492912
references.citation: J Affect Disord. 2000 Jan-Mar;57(1-3):13-24
references.pmid: 10708812
references.citation: J Neurosci. 2004 Mar 31;24(13):3235-41
references.pmid: 15056702
references.citation: Psychopharmacology (Berl). 2007 Jun;192(2):159-70
references.pmid: 17297636
references.citation: Science. 2013 May 3;340(6132):615-9
references.pmid: 23519215
references.citation: Neuropsychopharmacology. 2012 Mar;37(4):939-49
references.pmid: 22071871
references.citation: Biol Psychiatry. 2010 Mar 1;67(5):446-57
references.pmid: 20015486
references.citation: PLoS One. 2013 Aug 19;8(8):e63972
references.pmid: 23976938
references.citation: Neuropsychopharmacology. 2013 May;38(6):909-20
references.pmid: 23303069
references.citation: Cogn Process. 2010 Feb;11(1):57-84
references.pmid: 19876663
references.citation: J Clin Psychiatry. 2006 Nov;67(11):1735-40
references.pmid: 17196053
references.citation: J Consult Clin Psychol. 2010 Apr;78(2):169-83
references.pmid: 20350028
references.citation: Nat Rev Neurosci. 2008 Jan;9(1):46-56
references.pmid: 18073775
references.citation: Neurochem Res. 2006 Feb;31(2):167-76
references.pmid: 16673176
references.citation: Exp Brain Res. 2013 Aug;228(4):481-91
references.pmid: 23727882
references.citation: Pharmacol Ther. 2004 Feb;101(2):131-81
references.pmid: 14761703
references.citation: Neuropharmacology. 2005 Feb;48(2):204-14
references.pmid: 15695159
references.citation: Eur J Neurosci. 2009 Jul;30(2):299-306
references.pmid: 19614978
references.citation: Arch Gen Psychiatry. 2011 Jan;68(1):71-8
references.pmid: 20819978
references.citation: Neuropsychopharmacology. 2000 Apr;22(4):370-9
references.pmid: 10700656
references.citation: Neuropharmacology. 2000 Jan 28;39(3):463-70
references.pmid: 10698012
references.citation: Ther Adv Psychopharmacol. 2014 Apr;4(2):75-99
references.pmid: 24688759
references.citation: Neuropsychopharmacology. 2002 May;26(5):634-42
references.pmid: 11927188
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2013 Oct;162B(7):661-70
references.pmid: 24132898
references.citation: J Psychopharmacol. 2011 Nov;25(11):1453-61
references.pmid: 21956378
references.citation: Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20254-9
references.pmid: 22114193
references.citation: Science. 2003 Aug 8;301(5634):805-9
references.pmid: 12907793
references.citation: Acta Psychiatr Scand. 2011 Aug;124(2):102-19
references.pmid: 21534932
references.citation: Ther Adv Psychopharmacol. 2013 Jun;3(3):163-76
references.pmid: 24167688
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14470-5
references.pmid: 12388782
references.citation: J Psychopharmacol. 1991 Jan;5(4):305-15
references.pmid: 22282829